Chugai's RG6042 Receives MHLW's Orphan Drug Designation for Huntington's Disease in Japan
Shots:
- The MHLW has granted Chugai’s RG6042 an ODD for the expected treatment of Huntington's disease
- The RG6042 is currently being evaluated in P-III GENERATION HD1 study and is expected to delay the progression of Huntington’s disease as the first disease-modifying therapy
- RG6042 (ONIS-HTTRx) is an antisense oligonucleotide targeting HTT mRNA and has received FDA & EMA’s ODD for the Huntington's disease in May & Dec’2015 with EMA’s PRIME designation in 2018
Click here to read full press release/ article | Ref: Chugai | Image: Wikipedia
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com